Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.61 |
| ▸ | BCHE | P06276 | 3/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | LSS | P48449 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14149518 | 0.90 | SIGMAR1 (0.63) | PYCR1BCHESIGMAR1CYP1A2CYP2A6 | |
| SCHEMBL23423745 | 0.85 | PYCR1 (0.65) | PYCR1BCHESIGMAR1CYP1A2CYP2A6 | |
| SCHEMBL8088645 | 0.81 | SIGMAR1 (0.61) | PYCR1BCHESIGMAR1CYP1A2CYP2A6 | |
| SCHEMBL11932561 | 0.79 | SIGMAR1 (0.58) | PYCR1BCHESIGMAR1CYP1A2CYP2A6 | |
| SCHEMBL17447228 | 0.79 | PYCR1 (0.61) | PYCR1BCHESIGMAR1CYP1A2CYP2A6 | |
| SCHEMBL22912456 | 0.78 | BCHE (0.54) | PYCR1BCHESIGMAR1CYP1A2CYP2A6 | |
| SCHEMBL21118237 | 0.78 | HRH3 (0.54) | PYCR1SIGMAR1 | |
| SCHEMBL20021997 | 0.77 | BCHE (0.83) | BCHESIGMAR1CYP1A2CYP2A6SLC6A2 | |
| SCHEMBL23374539 | 0.77 | PYCR1 (0.59) | PYCR1BCHESIGMAR1CYP1A2CYP2A6 | |
| SCHEMBL13783914 | 0.77 | CYP1A2 (0.61) | PYCR1BCHESIGMAR1CYP1A2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082805-B1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INST FOR DRUG DISCOVERY LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| EP-1608377-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | Affinium Pharmaceuticals, Inc. (CA) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004082586-A2 | PHAMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | CMA1, CHIA, AADAC | PYCR1 4057/4885BCHE 140/4885SIGMAR1 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.